Abbott Settles Appeal in $495 Million Premature Infant Formula Lawsuit
What's Happening
Abbott Laboratories has settled its appeal of a $495 million jury verdict involving its specialized cow's milk-based formula for premature infants, ending one of the highest-profile cases in ongoing litigation over infant formula and necrotizing enterocolitis (NEC). The settlement resolves a lawsuit brought by the family of an Illinois girl who developed NEC after receiving Abbott's specialized formula in a neonatal intensive care unit (NICU).
Background of the Case
The lawsuit involved Similac Special Care, a specialized formula used in hospitals for premature infants. A Missouri jury in 2024 found Abbott liable and awarded $95 million in compensatory damages and $400 million in punitive damages. The family argued that Abbott failed to warn hospitals and clinicians about the potential risk of NEC, while Abbott maintained that its products are safe and medically necessary for many premature babies.
Understanding NEC
Necrotizing enterocolitis is a serious intestinal disease that primarily affects premature infants, causing inflammation and death of intestinal tissue, which can lead to severe infection, emergency surgery, long-term complications, or death. While medical research has shown that breast milk reduces the risk of NEC, Abbott and Mead Johnson maintain that current scientific evidence does not establish that their specialized formulas directly cause the disease.
Industry Impact
- Neonatal Care: The litigation continues to draw attention to feeding practices for premature infants and the importance of informed clinical decision-making in NICUs.
- Infant Formula Manufacturers: Abbott and Mead Johnson continue defending hundreds of similar lawsuits, creating ongoing legal and financial uncertainty.
- Healthcare Providers: NICUs and clinicians continue balancing the benefits of breast milk, donor milk, and specialized formulas while monitoring evolving legal and clinical developments.
- Healthcare Industry: The settlement closes one high-profile appeal but does not resolve the broader nationwide litigation involving specialized premature infant nutrition products.
Looking Ahead
Although this appeal has been settled, hundreds of similar lawsuits remain pending in federal and state courts. Future cases are expected to continue examining scientific evidence, product labeling, and manufacturers' responsibilities to warn clinicians about potential risks associated with specialized premature infant formulas.
Why This Matters
The settlement highlights the continued legal scrutiny surrounding nutrition for premature infants and underscores the importance of evidence-based neonatal care. While the agreement ends one major lawsuit, broader litigation continues to influence manufacturers, healthcare providers, and hospitals involved in neonatal care.
Key Takeaways
- Abbott settled its appeal of a $495 million verdict involving specialized premature infant formula.
- Settlement terms were not disclosed.
- The lawsuit alleged the company failed to warn about the risk of necrotizing enterocolitis (NEC) in premature infants.
- Abbott continues to deny its formula causes NEC.
- Hundreds of similar lawsuits remain pending against Abbott and Mead Johnson.
What This Means for Healthcare Marketers
The settlement underscores ongoing attention to neonatal nutrition, product safety, and risk communication in the healthcare industry. Neonatal care providers, children's hospitals, infant nutrition companies, medical device manufacturers, and healthcare legal and compliance organizations will continue monitoring developments in NEC litigation and neonatal care standards. For healthcare marketers, organizations involved in neonatal care, maternal and child health, hospital nutrition, patient safety, and clinical education represent high-intent opportunities for provider engagement, scientific communications, and evidence-based educational initiatives.